Stryker Co. (NYSE:SYK) Position Increased by Community Bank N.A.

Community Bank N.A. grew its holdings in Stryker Co. (NYSE:SYK) by 3.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,594 shares of the medical technology company’s stock after purchasing an additional 215 shares during the period. Community Bank N.A.’s holdings in Stryker were worth $2,374,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Stevens Capital Management LP acquired a new position in shares of Stryker in the 4th quarter valued at about $901,000. Banco de Sabadell S.A increased its holdings in shares of Stryker by 1.3% in the 4th quarter. Banco de Sabadell S.A now owns 5,261 shares of the medical technology company’s stock valued at $1,897,000 after purchasing an additional 66 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Stryker in the 4th quarter valued at about $660,000. KLP Kapitalforvaltning AS acquired a new position in shares of Stryker in the 4th quarter valued at about $41,749,000. Finally, Umpqua Bank increased its holdings in shares of Stryker by 2.7% in the 4th quarter. Umpqua Bank now owns 5,516 shares of the medical technology company’s stock valued at $2,001,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.8 %

Shares of Stryker stock opened at $371.38 on Friday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $384.28 and its 200-day simple moving average is $374.03. The company has a market cap of $141.71 billion, a price-to-earnings ratio of 47.86, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 EPS. As a group, sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research reports. Barclays increased their price objective on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Finally, Truist Financial increased their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.